Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 228

Results For "SPE"

5017 News Found

Merck invests € 300 million in new Life Science production site in South Korea
News | March 21, 2024

Merck invests € 300 million in new Life Science production site in South Korea

New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics


IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion
News | March 21, 2024

IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion

Pharma Solutions operates 10 research and development and/or production sites globally


Elegen launches Enfina DNA enhancement for rapid synthesis of highly complex DNA
Biotech | March 21, 2024

Elegen launches Enfina DNA enhancement for rapid synthesis of highly complex DNA

Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days


AstraZeneca buys biopharmaceutical company Fusion
News | March 20, 2024

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer


Carbogen Amcis (Shanghai) completed ANVISA Audit
Drug Approval | March 19, 2024

Carbogen Amcis (Shanghai) completed ANVISA Audit

A five-day inspection was concluded successfully with no critical and no major observations raised


Grace expands CDMO capacity by 25% of South Haven facility in Michigan
News | March 19, 2024

Grace expands CDMO capacity by 25% of South Haven facility in Michigan

Additional capacity broadens Grace’s fine chemical capabilities for API production


Sun Pharmaceuticals receives approval for Winlevi in Australia
Drug Approval | March 19, 2024

Sun Pharmaceuticals receives approval for Winlevi in Australia

Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older


AstraZeneca to acquire Amolyt Pharma
News | March 18, 2024

AstraZeneca to acquire Amolyt Pharma

Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition


Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
News | March 17, 2024

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr

Both organisations enter into a long- term collaboration to expand patient access in India